News
Expedia (EXPE) Beats Q2 Earnings and Revenue Estimates
Expedia (EXPE) came out with quarterly earnings of $4.24 per share, beating the Zacks Consensus Estimate of $4.14 per share. This compares to earnings of $3.51 per share a year ago. These figures
Texas Roadhouse (TXRH) Lags Q2 Earnings Estimates
Texas Roadhouse (TXRH) came out with quarterly earnings of $1.86 per share, missing the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $1.79 per share a year ago. These
Ascend Wellness Holdings, Inc. (AAWH) Reports Q2 Loss, Misses Revenue Estimates
Ascend Wellness Holdings, Inc. (AAWH) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.1 per share a year ago
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago. These
The Trade Desk (TTD) Lags Q2 Earnings Estimates
The Trade Desk (TTD) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.39 per share a year ago. These
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago. These figures
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to a loss of $1.31 per share a year ago. These figures are
AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down
Over the past 52 weeks, AppLovin (NASDAQ: APP) has been one of the biggest stock market standouts. As of the Aug. 6 close, shares have surged by a whopping 446%. The company has an incredibly
Top Research Reports for NVIDIA, Palantir & Coca-Cola
Thursday, August 7, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA
Microsoft Stock Gains as Analysts Boost Price Targets
Microsoft Corporation (NASDAQ: MSFT) delivered an earnings report that can be considered a blowout, even for a mega-cap company with high expectations. Microsoft beat on revenue and earnings and
Buy the Spike in AppLovin Stock after Q2 earnings?
AppLovin APP continued its growing popularity as one of the market’s top momentum stocks after exceeding its Q2 expectations on Wednesday evening.
The marketing and technology provider for apps has
Constellation Energy’s Earnings Beat Signals a New Era
Constellation Energy (NASDAQ: CEG) delivered a solid second-quarter earnings report on Aug. 7, beating analyst estimates and reinforcing its crucial role in the digital economy. This strong
Appian (APPN) Reports Q2 Earnings: What Key Metrics Have to Say
Appian (APPN) reported $170.64 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $0 for the same period compares to -$0.26 a year ago.
The
Compared to Estimates, Targa Resources (TRGP) Q2 Earnings: A Look at Key Metrics
Targa Resources, Inc. (TRGP) reported $4.26 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 19.6%. EPS of $2.87 for the same period compares to $1.33 a
Sabre (SABR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, Sabre (SABR) reported revenue of $687.15 million, down 10.4% over the same period last year. EPS came in at -$0.02, compared to -$0.05 in the year-ago quarter.
The
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
Investors responded with optimism following CVS Health’s CVS second-quarter 2025 earnings release last week, buoyed by better-than-expected earnings and revenue growth, improved segment performance
Epam (EPAM) Beats Q2 Earnings Estimates (Revised)
Epam (EPAM) came out with quarterly earnings of $2.77 per share, missing the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.45 per share a year ago. These figures are
Allegiant Q2 Earnings Surpass Estimates, Decline Year Over Year
Allegiant Travel Company (ALGT) reported second-quarter 2025 earnings of $1.23 per share, which surpassed the Zacks Consensus Estimate of 83 cents per share. However, the bottom line declined 30.5%
Gibraltar Q2 Earnings & Sales Lag Estimates, Both Rise Y/Y, Stock Down
Gibraltar Industries, Inc. ROCK reported lower-than-expected second-quarter 2025 results, wherein its earnings and net sales missed the Zacks Consensus Estimate. However, the top and bottom lines
AIG Q2 Earnings Beat on Higher North America Commercial Premiums
American International Group, Inc. AIG reported second-quarter 2025 adjusted earnings per share of $1.81, which outpaced the Zacks Consensus Estimate by 14.6%. The bottom line surged 56% year over
Arhaus, Inc. (ARHS) Reports Q2 Earnings: What Key Metrics Have to Say
Arhaus, Inc. (ARHS) reported $358.44 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 15.7%. EPS of $0.25 for the same period compares to $0.16 a year
Here's What Key Metrics Tell Us About Amplitude (AMPL) Q2 Earnings
For the quarter ended June 2025, Amplitude, Inc. (AMPL) reported revenue of $83.27 million, up 13.6% over the same period last year. EPS came in at $0.01, compared to $0 in the year-ago quarter.
The
Oportun Financial (OPRT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Oportun Financial Corporation (OPRT) reported $234.3 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.4%. EPS of $0.31 for the same period compares to


